Teaching hospital

Mishe and SUNY Downstate Health Sciences University Partner to Offer Real Transparent Pricing for Comprehensive Healthcare Services

Retrieved on: 
torsdag, mars 28, 2024
CFO, Partnership, Patient, Insurance, Downstate, Teaching hospital, SUNY Downstate Medical Center, Physician, Fear

BROOKLYN, N.Y., March 28, 2024 /PRNewswire/ -- Mishe (say "mish-e"), an innovator in direct healthcare, announces the launch of Downstate's Transparent Access Plan, making SUNY Downstate Health Sciences University the first hospital system in the US to offer transparent upfront pricing for its comprehensive suite of inpatient and outpatient healthcare services.

Key Points: 
  • BROOKLYN, N.Y., March 28, 2024 /PRNewswire/ -- Mishe (say "mish-e"), an innovator in direct healthcare, announces the launch of Downstate's Transparent Access Plan, making SUNY Downstate Health Sciences University the first hospital system in the US to offer transparent upfront pricing for its comprehensive suite of inpatient and outpatient healthcare services.
  • "Our solutions empower providers and payers to compliantly offer transparent prices so patients can confidently access care.
  • We're thrilled to partner with University Hospital at Downstate and University Physicians of Brooklyn to become the source of truth for real pricing across the care continuum."
  • "This historic partnership is a turning point for the healthcare industry," said Sean Smith, CFO of University Hospital at Downstate.

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

Retrieved on: 
måndag, mars 11, 2024
Eosinophil, Fever, Week, Headache, OX40L, Conjunctivitis, Scleroderma, Teaching hospital, Atopic dermatitis, Upper respiratory tract infection, Part, Asthma, TARC, Conference, AAD, Safety, Biomarker, Part Two, Hidradenitis suppurativa, IGA, Patient, Inflammation, Chills, Moa, Serum, American Academy, Pharmaceutical industry

The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.

Key Points: 
  • The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.
  • Overall rates of treatment-emergent adverse events (TEAEs) were 69.8% for continued amlitelimab treatment, 71.9% for the amlitelimab withdrawal-arm and 66.7% for placebo.
  • TEAEs more commonly observed included headache (11.6% amlitelimab continuation, 3.9% amlitelimab withdrawal, 6.7% placebo), upper respiratory tract infection (9.3% amlitelimab continuation, 5.5% amlitelimab withdrawal, 20% placebo).
  • Amlitelimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts

Retrieved on: 
torsdag, mars 7, 2024
Therapy, CNRS, Target, Newcastle University, Facial muscles, Biotechnology, Professor, Teaching hospital, SAB, Neuromuscular disease, Ageing, Leiden University Medical Center, HD, DMD, Duchenne muscular dystrophy, Inflammation, LUMC, Mitochondrion, Gene therapy, Scientific method, Genetics, Knowledge, Leibniz Association, Publication, Translational research, Respiratory disease, Research, COPD, Pharmaceutical industry

OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.

Key Points: 
  • OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.
  • Dr. Jon Rees, Chief Executive Officer of MitoRx, said, “We are thrilled to welcome Dr.
  • Le Guiner, Dr. Filipovic, Professor Hansbro, and Professor Aartsma-Rus, to our Scientific Advisory Board.
  • She has a visiting professorship at the John Walton Muscular Dystrophy Research Center at the UK’s Newcastle University.

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

Retrieved on: 
måndag, mars 4, 2024
MIRA, University College Dublin, Doctor of Philosophy, MD, Teaching hospital, Single-domain antibody, EST, Hidradenitis suppurativa, Inflammation, AAD, Safety, Patient, PST, Moonlake, Venereology, HS, American Academy, Pharmaceutical industry

Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: “We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation.

Key Points: 
  • Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: “We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation.
  • The presentation will be held on Sunday 10 March at 14:00 PST / 17:00 EST / 23:00 CET during the late breaking research session 2 (S050) in room 20B.
  • Key members of the MoonLake team, including the executive leadership team, will attend AAD.
  • This was followed by an announcement in October 2023, reporting from the trial at 24 weeks, further establishing sonelokimab as a highly promising and differentiated therapeutic solution for HS.

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Retrieved on: 
onsdag, februari 28, 2024
ASRS, Senior, Paris Diderot University, SAB, Reno 1868 FC, Growth, Visual acuity, University, DED, Telecanthus, Organization, Principal, Teaching hospital, Retina, Anthropology, Diabetic retinopathy, Therapy, OCS, Inflammation, CSO, DME, American Academy, Simmons University, M.A, Clinical research, ASCRS, Society, Cerebral edema, Eastern Virginia Medical School, Patient, Partner (business rank), Medicine, Pharmaceutical industry

In-person and virtual R&D Day today from 9:00 AM to 11:00 AM EST at the InterContinental New York Barclay.

Key Points: 
  • In-person and virtual R&D Day today from 9:00 AM to 11:00 AM EST at the InterContinental New York Barclay.
  • “2024 promises to be another exciting year for Oculis as we advance our late-stage clinical development programs.
  • I am certain that the extensive experience each of them brings will be invaluable to Oculis,” said Riad Sherif, M.D., Chief Executive Officer of Oculis.
  • Oculis also announced today key executive appointments to bolster its leadership and scientific advisory teams.

Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial

Retrieved on: 
måndag, februari 26, 2024
Health, Medical Devices, Health Technology, Clinical Trials, Research, Science, Biotechnology, Foam, PMA, Teaching hospital, FDA, Quality of life, News, Food, IDE, American International Group, Chronic obstructive pulmonary disease, Safety, Lung, Endobronchial valve, Patient, Periodic breathing, Corporation, COPD, Fissure, Medical device

Successful treatment with the AeriSeal System is followed by treatment with commercially available Zephyr® Valves.

Key Points: 
  • Successful treatment with the AeriSeal System is followed by treatment with commercially available Zephyr® Valves.
  • Pulmonx received a staged IDE approval by the Food and Drug Administration (FDA) to commence the CONVERT II Pivotal Trial for the AeriSeal System in late 2023.
  • Severe COPD/emphysema patients with collateral ventilation confirmed with Pulmonx’s proprietary Chartis® Pulmonary Assessment System (Chartis) undergo the AeriSeal System treatment.
  • “We hope the CONVERT II Trial will move us closer to the goal of helping patients with collateral ventilation to also receive benefit from our Zephyr Valves.”

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies

Retrieved on: 
onsdag, februari 21, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CTE, Multimedia, Teaching hospital, Cancer, NHS foundation trust, Drug development, Cancer Research UK, Safety, Bone marrow, Lymphoid leukemia, Patient, Clinical trial, Cancer research

Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-Cell Engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial.

Key Points: 
  • Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-Cell Engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial.
  • This trial is evaluating the Company’s first-in-class biologic CAR T-Cell Engager, ALETA-001, for the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19-targeting CAR T-cell therapy.
  • View the full release here: https://www.businesswire.com/news/home/20240221259676/en/
    Cancer Research UK’s Centre for Drug Development is sponsoring and conducting the Phase 1/2 clinical trial of ALETA-001, the lead agent in Aleta's portfolio.
  • Clinical evaluation of ALETA-001 is a key milestone toward a much-needed treatment option for the many cancer patients whose CD19-targeted CAR T-cell therapies ultimately stop working.

Thompson Hine Names New Managing Partner

Retrieved on: 
onsdag, februari 21, 2024
Legal, Trucking, Consulting, Transport, Accounting, Professional Services, Philanthropy, DEI (Diversity, Equity and Inclusion), Logistics, Supply Chain Management, Other Philanthropy, African Americans, Woman, Alumni, Hine, The Cleveland Foundation, Multimedia, Bloomberg, Ohio State Buckeyes, Teaching hospital, Learning, Rock, Marburn Academy, OSU, Columbus metropolitan area, Ohio, University School, Ohio State University, The National Law Journal, ABA Journal, Health care, United Way, Sport, FLSA, Conference, University, The American Lawyer, Organization, Real-time, Law, Financial Times, Management

Thompson Hine LLP , a law firm recognized for innovation, announced today that it has elected Tony White as its managing partner.

Key Points: 
  • Thompson Hine LLP , a law firm recognized for innovation, announced today that it has elected Tony White as its managing partner.
  • He has served for over 13 years on the executive committee, the firm’s governing body, and for 11 years, he has been the national hiring partner, supervising Thompson Hine’s lateral partner and senior counsel recruiting and hiring.
  • She led the firm through changes in its service delivery model, making Thompson Hine one of the first firms to do so.
  • FT noted that “Thompson Hine is now ranked as one of the top five firms in the U.S. for client service.

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

Retrieved on: 
tisdag, februari 20, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Therapeutic index, DOI, Nuclear medicine, Prostate cancer, Neoplasm, Isotope, Teaching hospital, Physician, Safety, Food, PSMA, Treatment, Hope, Manuscript, Therapy, Patient, Optimism, Journal, PSA, Legislation, Prostate-specific antigen, Metastasis, Medical imaging

The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).

Key Points: 
  • The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).
  • In the 4 consecutive patients with metastatic prostate cancer who were evaluated, when looking at radiologic progression free survival (rPFS), 2 patients had not progressed at 24 and 18 months of follow-up.
  • 177Lu-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted radiopharmaceutical for the treatment of prostate cancer, and the lead candidate in Blue Earth Therapeutics’ development of next generation therapeutic radiopharmaceuticals.
  • “These promising clinical data give us further optimism in advancing 177Lu-rhPSMA forward in clinical development, with the hope to help treat patients with metastatic prostate cancer.

IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024

Retrieved on: 
måndag, mars 4, 2024
Woman, PAIN, Neoplasm, Teaching hospital, Patient satisfaction, Abdominal wall, Endometriosis, Freezing, Visual analogue scale, Safety, Patient, MRI, Medical imaging

Five doctors participated in the study, including interventional radiologist and ProSense® user Prof. Julien Frandon, who has previously led hands-on training sessions with ProSense® at multiple medical conferences.

Key Points: 
  • Five doctors participated in the study, including interventional radiologist and ProSense® user Prof. Julien Frandon, who has previously led hands-on training sessions with ProSense® at multiple medical conferences.
  • The investigator-initiated single-site study enrolled 7 women, ages 30-45 years, with endometriosis in the abdominal wall and para-diaphragmatic areas.
  • One month following treatment, assessment by MRI revealed hemorrhagic signal had disappeared and necrotic changes developed.
  • We are very pleased that all patients treated in this study were relieved of their endometriosis condition and pain within as little as a month following treatment," stated IceCure CEO Eyal Shamir.